Study Summary
A multicenter, open, non-randomized, phase I/II, two-phase clinical study. The dose exploration phase was phase I, and the dose extension phase was phase II.
Want to learn more about this trial?
Request More InfoInterventions
VGB-R04GENETIC
A novel, bioengineered adeno-associated viral (AAV) vector carrying human factor IX variant
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Shanghai Vitalgen Biopharma Co.,Ltd. | Shanghai | China |